{"version":"1.0","type":"link","title":"Durable clinical benefit and progression-free survival in patients with PD-L1 ≥50% NSCLC receiving pembrolizumab: Impact of nutritional and inflammatory markers.","author_name":"Yamakawa H 외","author_url":"https://prs-insight.online/author/Yamakawa%20H","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/97061","thumbnail_width":1200,"thumbnail_height":630}